IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
2023年7月11日 - 9:17PM
via IBN – IBN, a multifaceted communications organization engaged
in connecting public companies to the investment community, is
pleased to announce the release of the latest episode of The
Bell2Bell Podcast as part of its sustained effort to provide
specialized content distribution via widespread syndication
channels.
The Bell2Bell Podcast delivers informative updates and exclusive
interviews with executives operating in fast-moving industries.
Bell2Bell’s latest podcast features Amir Reichman, CEO of BiondVax
Pharmaceuticals Ltd. (NASDAQ: BVXV). BiondVax’s pipeline is based
on an innovative platform technology of alpaca-derived nanosized
antibodies, known as Nanobodies or NanoAbs, addressing infectious
and autoimmune diseases with large unmet medical needs such as
COVID-19, psoriasis, psoriatic arthritis, asthma and macular
degeneration.
This appearance follows a December 2022 interview between
Reichman and host Stuart Smith. To review the first part of the
series, visit The Stock2Me Podcast.
To begin the latest interview, Reichman discussed the company’s
recent achievements, as detailed in a letter to shareholders issued
late last year.
“At the end of 2022, we did a round of financing and raised
about $8 million. We also started the negotiations to in-license
the next antibody from the Max Planck Institute – namely the
antibody for targeting interleukin-17 (IL-17) for the treatment of
psoriasis,” Reichman said. “We have now in-licensed the IL-17
nanobody. This is a highly promising drug.”
“If we look at the market, psoriatic patients today have several
options for treatment. For example, plaque psoriasis patients have
creams and other topical drugs, biologics and oral drugs… The
topicals are not highly sophisticated drugs to say the least, and
they come with a considerable profile of side effects. When a
person needs to take steroids once in a while for an infection,
they can tolerate it, but when you need to take steroids for an
autoimmune disease with chronic inflammation, you create tolerance
and deal with potential side effects… The biologics are highly
potent, but they are restricted to moderate and severe cases of
psoriasis; this accounts for only 15% of patients with psoriasis.
The 85% that are left have to choose between drugs based on 1960s
and 1970s technology. There hasn’t been much breakthrough in recent
years to serve these patients.”
“When you are talking about autoimmune disease, you are talking
about chronic disease. Therefore, the patient should use this drug
for life… The total [annual] sales of anti-interleukin-17
monoclonal antibodies are about $7.5 billion. If you take all of
the other psoriasis biologics, the market is about $10 billion per
year, targeting only severe cases. What we want to do is generate
an axis for a highly potent, highly specific drug that’s safe to
use for mild-to-moderate psoriasis cases. This is where our
nanobodies are the best fit… We can inject it in an affordable way
directly to the lesion… to provide relief and alleviate
inflammation. Then, the next treatment will come only with the next
flareup, six months or a year later.”
The company expects to complete a proof-of-concept trial later
this year, followed later by human clinical trials.
Join IBN’s Stuart Smith and Amir Reichman, CEO of BiondVax
Pharmaceuticals Ltd. (NASDAQ: BVXV), to learn more about the
company’s efforts to address the underserved mild-to-moderate
psoriasis treatment market by leveraging its novel NanoAbs
platform.
To hear the episode and subscribe for future podcasts,
visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to
reinforce IBN’s commitment to the expansion of its robust network
of brands, client partners, followers, and the growing IBN Podcast
Series. For more than 17 years, IBN has leveraged this commitment
to provide unparalleled distribution and corporate messaging
solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a
visual timeline, visit: https://IBN.fm/TimeLine
About BiondVax
BiondVax Pharmaceuticals Ltd. is a biotechnology company focused
on developing, manufacturing and commercializing innovative
immunotherapeutic products primarily for the treatment of
infectious and autoimmune diseases. Since its inception, the
company has executed eight clinical trials including a seven
country, 12,400 participant Phase 3 trial of its prior vaccine
candidate and has built a state-of-the-art manufacturing facility
for biopharmaceutical products. With highly experienced
pharmaceutical industry leadership, BiondVax is aiming to
develop a pipeline of diversified and commercially viable products
and platforms beginning with an innovative nanosized antibody
(NanoAb) pipeline. For more information, visit the company’s
website at www.BiondVax.com
About IBN
IBN consists of financial brands introduced to the investment
public over the course of 17+ years. With IBN, we have amassed a
collective audience of millions of social media followers. These
distinctive investor brands aim to fulfill the unique needs of a
growing base of client-partners. IBN will continue to expand our
branded network of highly influential properties, leveraging the
knowledge and energy of specialized teams of experts to serve our
increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1)
access to a network of wire solutions via InvestorWire to reach all
target markets, industries and demographics in the most effective
manner possible; (2) article and editorial syndication to 5,000+
news outlets; (3) Press Release Enhancement to ensure maximum
impact; (4) full-scale distribution to a growing social media
audience; (5) a full array of corporate communications solutions;
and (6) total news coverage solutions.
For more information, please visit
https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or re-published:
http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBNLos Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
BiondVax Pharmaceuticals (NASDAQ:BVXV)
過去 株価チャート
から 4 2024 まで 5 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
過去 株価チャート
から 5 2023 まで 5 2024